1. Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials. (2nd January 2022) Authors: Gordon, K. B.; Reich, K.; Crowley, J. J.; Korman, N. J.; Murphy, F. T.; Poulin, Y.; Spelman, L.; Yamauchi, P. S.; Mendelsohn, A. M.; Parno, J.; Rozzo, S. J.; Ellis, C. N. Journal: Journal of dermatological treatment Issue: Volume 33:Number 1(2022) Page Start: 219 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗